Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 3/20 | 0.46 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | CCNK | O75909 | 2/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3867365 | 0.91 | ALDH1A1 (0.51) | EPHX1ALDH1A1KDM5AKDM5BKDM5C | |
| SCHEMBL5746443 | 0.91 | ALDH1A1 (0.51) | EPHX1ALDH1A1KDM5AKDM5BKDM5C | |
| SCHEMBL5748631 | 0.90 | ALDH1A1 (0.53) | EPHX1ALDH1A1KDM5BGRM5LMNA | |
| SCHEMBL3856964 | 0.90 | ALDH1A1 (0.53) | EPHX1ALDH1A1KDM5BGRM5LMNA | |
| SCHEMBL3861456 | 0.90 | ALDH1A1 (0.53) | EPHX1ALDH1A1KDM5BGRM5LMNA | |
| SCHEMBL5746899 | 0.90 | ALDH1A1 (0.53) | EPHX1ALDH1A1KDM5BGRM5LMNA | |
| SCHEMBL5909080 | 0.86 | VNN1 (0.53) | ALDH1A1KDM5ACCNKCDK12GRM5 | |
| SCHEMBL5909117 | 0.86 | ALDH1A1 (0.52) | ALDH1A1KDM5ACCNKCDK12GRM5 | |
| SCHEMBL5909284 | 0.86 | VNN1 (0.53) | ALDH1A1KDM5ACCNKCDK12GRM5 | |
| SCHEMBL5745597 | 0.84 | KDM5B (0.53) | ALDH1A1KDM5BCCNKCDK12GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | claimed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | claimed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | claimed |
| US-7592466-B2 | Ureas having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1680415-B1 | PYRROLIDINYL UREA DERIVATIVES AS ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | ABBVIE INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160806-A1 | N-benzyl-N'-{(3R)-1-[(6-methylpyridin-3-yl)carbonyl]pyrrolidin-3-yl}urea | FLT4, FLT1, KDR | EPHX1 2403/4885ALDH1A1 1710/4885KDM5A 1429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.